Sign in
TerminatedPhase 2

Dual-Orexin Antagonism As a Mechanism for Improving Sleep and Drug Abstinence in Opioid Use Disorder

Key facts

Who runs it
Wayne State University
Where
Detroit, United StatesSee the site
Trial code
Status
Terminated
Phase
Phase 2
People taking part
37 people enrolled
Started
1 Feb 2021
Ended
30 Jul 2024
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Suvorexant
  • Suvorexant Placebo
Record updated
25 September 2024
Why it stopped
Did not meet enrollment goals.

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Age 18-70 years old
  • Males and non-pregnant females who agree to medically accepted birth control for the duration of the study
  • Meet DSM-5 criteria for opioid use disorder (any severity level) alone or comorbid with stable medical diseases (except for certain medications [see below])

Who cannot take part

  • Smoking during the night (11pm-7am). Nicotine replacement therapy is allowed
  • Medications including anxiolytics, hypnotics (both prescription and OTC), sedating antidepressants, anticonvulsants, sedating H1 antihistamines (non-sedating second generation H4 antihistamines are allowed), systemic steroids, respiratory stimulants and decongestants, prescription and OTC stimulants, prescription and OTC diet aids, herbal preparations, and narcotic analgesics. All medications and doses will be documented
  • Acute/unstable illness: conditions making it unsafe for participation, conditions with potential to disturb sleep (i.e. acute pain, respiratory infection)
  • Chronic illnesses; renal failure, liver disease, seizures, and dementing illnesses
  • Current psychiatric disease: psychosis, bipolar disorder, PTSD
  • Sleep-disordered breathing and periodic leg movements (PLMs) defined as ≥ 10 apnea-hypopneas or PLM events related to EEG arousal per hour of sleep time, or any other primary sleep (e.g. narcolepsy, restless legs syndrome) or circadian disorder
  • Body mass index >38
  • Night-shift work, which would alter circadian rhythm and be a confound in this trial

Where in United States

  • Wayne State UniversityDetroit, United States

About the trial

What the trial wants to find out

Summary of Study Protocol. This project is designed to test neurobehavioral mechanisms underlying effects of the dual orexin-1/2 receptor antagonist suvorexant on sleep efficiency and opioid abstinence, and whether these outcomes are independent of one another. This will be the first study to investigate whether suvorexant improves outpatient opioid abstinence and sleep efficiency; and whether improving sleep mediates the improved opioid abstinence outcome. 120 participants with opioid use disorder (OUD) will complete this intent-to-treat study.

The 2 groups in the trial

  • Suvorexant placeboPlacebo, for comparison

    Placebo (inert) tablet

  • Suvorexant 20mgTreatment being tested

    Suvorexant 20mg tablet

    Treatment: Suvorexant

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
25 September 2024